Clinical Trial Detail

NCT ID NCT03241927
Title Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nina Bhardwaj
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.